Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus

Jorge A. Soto, Felipe Melo-González, Claudia A. Riedel, Susan M. Bueno, Alexis M. Kalergis

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

2 Citas (Scopus)


Cutaneous lupus erythematosus (CLE) is an autoimmune disorder like systemic lupus erythematosus (SLE). Both SLE and CLE characterize autoantibody secretion and immune cell recruitment. In particular, CLE can be divided into three more frequent types, varying in the severity of the skin lesions they present. The role of type I IFN was shown to be one of the leading causes of the development of this pathology in the skin. Different treatments have been developed and tested against these different variants of CLE to decrease the increasing levels of CLE in humans. In this article, a literature revision discussing the similarities between SLE and CLE is carried out. In addition, new advances in understanding the development of CLE and the leading treatments being evaluated in animal models and clinical trials are reviewed.

Idioma originalInglés
PublicaciónInternational Journal of Molecular Sciences
EstadoPublicada - 14 sep. 2022

Áreas temáticas de ASJC Scopus

  • Catálisis
  • Biología molecular
  • Espectroscopia
  • Informática aplicada
  • Química física y teórica
  • Química orgánica
  • Química inorgánica


Profundice en los temas de investigación de 'Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus'. En conjunto forman una huella única.

Citar esto